Anne Suhr Thykjær

Anne Suhr Thykjær

Auto-generated profile, based on publicly available information

Anne Suhr Thykjær

Department of Clinical Research University of Southern Denmark Odense Denmark

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2017 in Acta Ophthalmologica
Verified
Journal Article
Closed access
PDF file
KLKristian Lundberg
Kristian Lundberg
ATAnne Suhr Thykjær
Anne Suhr Thykjær
RHRasmus Søgaard Hansen
Rasmus Søgaard Hansen
AVAnders Højslet Vestergaard
Anders Højslet Vestergaard
NJNina Jacobsen
Nina Jacobsen
JGJakob Grauslund
Jakob Grauslund

14 December 2016 in Acta Ophthalmologica
Verified
Journal Article
Closed access
PDF file
ATAnne Suhr Thykjær
Anne Suhr Thykjær
KLKristian Lundberg
Kristian Lundberg
JGJakob Grauslund
Jakob Grauslund

12 August 2022 in Acta Diabetologica
Verified
Journal Article
Open access
PDF file
ATAnne Suhr Thykjær
Anne Suhr Thykjær
NAN. Andersen
N. Andersen
TBToke Bek
Toke Bek
SHSteffen Heegaard
Steffen Heegaard
JHJavad Nouri Hajari
Javad Nouri Hajari
JGJakob Grauslund
Jakob Grauslund
Aims: A nationwide diabetic retinopathy (DR) screening program has been established in Denmark since 2013. We aimed to perform an evaluation of adherence to DR screenings and to examine whether non-adherence was correlated to DR progression. Methods: The population consisted of a register-based cohort, who participated in the screening program from 2013 to 2018. We analyzed age, gender, marital status, DR level (International Clinical DR severity scale, none, mild-, moderate-, severe non-proliferative DR (NPDR) and proliferative DR (PDR)), comorbidities and socioeconomic factors. The attendance pattern of patients was grouped as either timely (no delays > 33%), delayed (delays > 33%) or one-time attendance (unexplained). Results: We included 205,970 patients with 591,136 screenings. Rates of timely, delayed and one-time attendance were 53.0%, 35.5% and 11.5%, respectively. DR level at baseline was associated with delays (mild-, moderate-, severe NPDR and PDR) and one-time attendance (moderate-, severe NPDR and PDR) with relative risk ratios (RRR) of 1.68, 2.27, 3.14, 2.44 and 1.18, 2.07, 1.26, respectively (P < 0.05). Delays at previous screenings were associated with progression to severe NPDR or PDR (hazard ratio (HR) 2.27, 6.25 and 12.84 for 1, 2 and 3+ delays, respectively). Any given delay doubled the risk of progression (HR 2.28). Conclusions: In a national cohort of 205,970 patients, almost half of the patients attended DR screening later than scheduled or dropped out after first screening episode. This was, in particular, true for patients with any levels of DR at baseline. DR progression in patients with delayed attendance, increased with the number of missed appointments.

3 October 2022 in Acta Ophthalmologica
Verified
Journal Article
Open access
JGJakob Grauslund
Jakob Grauslund
FPFrederik Nørregaard Pedersen
Frederik Nørregaard Pedersen
NANis Andersen
Nis Andersen
JAJens Andresen
Jens Andresen
TBToke Bek
Toke Bek
LSLonny Stokholm
Lonny Stokholm
Purpose: The purpose of the study was to evaluate the prevalence and incidence of diabetic retinopathy (DR) along with associated markers in patients with type 2 diabetes in the Danish DR‐screening programme.Methods: We included all persons with type 2 diabetes in the Danish Registry of Diabetic Retinopathy, who had attended at least one episode of DR screening in 2013–2018. DR was classified as levels 0–4 indicating increasing severity. Data were linked with various national health registries to retrieve information on diabetes duration, marital status, comorbidity and systemic medication.Results: Among 153 238 persons with type 2 diabetes, median age and duration of diabetes were 66.9 and 5.3 years and 56.4% were males. Prevalence and 5‐year incidences of DR, 2‐step‐or‐more progression of DR and progression to proliferative DR (PDR) were 8.8%, 3.8%, 0.7% and 0.2%, respectively. In multivariable models, leading markers of incident DR and progression to PDR were duration of diabetes (HR 1.98, 95% CI 1.87–2.09; HR 2.89, 95% CI 2.34–3.58 per 10 years of duration) and use of insulin (HR 1.88, 95% CI 1.76–2.01; HR 2.40, 95% CI 1.84–3.13), while the use of cholesterol‐lowering medicine was a protecting marker (HR 0.87, 95% CI 0.81–0.93; HR 0.70, 95% CI 0.52–0.93). From 2013 to 2015, 3‐year incidence rates of PDR decreased from 1.22 to 0.45 events per 1000 person‐years.Conclusion: Nationally, among Danish individuals with type 2 diabetes attending DR screening, we identified duration of diabetes and use of insulin as the most important predictor for the development of DR, while cholesterol‐lowering medicine was a protective factor.

13 December 2022 in Acta Ophthalmologica
Verified
Journal Article
Open access
SSSigne Sperling
Signe Sperling
LSLonny Stokholm
Lonny Stokholm
ATAnne Suhr Thykjær
Anne Suhr Thykjær
FPFrederik Nørregaard Pedersen
Frederik Nørregaard Pedersen
SMSören Möller
Sören Möller
JGJakob Grauslund
Jakob Grauslund
Purpose: We aimed to investigate if diabetic retinopathy (DR), glaucoma and/or ocular hypertension (OHT) are prospectively linked, as previous studies have proposed cross‐sectional associations, but longitudinal data from larger cohorts are lacking.Methods: We performed a bidirectional 5 years prospective, registry‐based cohort study. We extracted data from national registers, including the Danish Registry of Diabetic Retinopathy, the Danish Civil Registration System, the Danish National Patient Register and the Danish National Prescription Registry. DR level was defined by the highest level of the two eyes. Glaucoma and/or OHT was defined by diagnostic codes (H40*) or at least three redeemed prescriptions of glaucoma medication (S01E*) within 1 year.We included 205 970 persons with diabetes and 1 003 170 age‐ and gender‐matched non‐diabetes controls. Exposures were level‐specific DR (i) and glaucoma and/or OHT (ii), and outcomes were hazard ratios (HRs) for 5 years incident glaucoma and/or OHT (i) and DR (ii).Results: Persons with diabetes were more likely to develop glaucoma and/or OHT (multivariable adjusted HR 1.11, 95% CI 1.06–1.15), but this did not depend on the level of DR. In persons with diabetes, those with glaucoma and/or OHT were more likely to develop DR (multivariable adjusted HR 1.12, 95% CI 1.03–1.23) within 5 years.Conclusion: In a national cohort, diabetes associated with a little higher risk of upcoming glaucoma and/or OHT, and, inversely, the presence of the latter predicted a higher risk of incident DR. Nevertheless, our data do not seem to justify including glaucoma evaluation in the national Danish DR‐screening programme.

16 January 2018 in Acta Ophthalmologica
Verified
Journal Article
Open access
PDF file
KLKristian Lundberg
Kristian Lundberg
AVAnders Højslet Vestergaard
Anders Højslet Vestergaard
NJNina Jacobsen
Nina Jacobsen
ATAnne Suhr Thykjær
Anne Suhr Thykjær
RHRasmus Søgaard Hansen
Rasmus Søgaard Hansen
JGJakob Grauslund
Jakob Grauslund
Purpose: To describe the relationship between choroidal thickness (CT) and myopia in relation to physical activity (PA) in a population‐based child cohort.Methods: In a prospective study of 307 children from theCHAMPSStudy Denmark, we used objective data from GT3X accelerometer worn at four periods between 2009 and 2015 to determine the amount and intensity ofPA. Intensity was estimated as counts/minutes, and cut‐off points were defined at four intensity levels. Eye examinations were performed in 2015 and included autorefraction in cycloplegia, axial length (AL) by biometric and fovea‐centred enhanced depth imaging optical coherence tomography. By a semi‐automated method, we measured theCTat 17 targets per eye representing anatomically different locations (subfoveal, 1 and 3 millimetre in each direction of fovea).Results: Mean age at the eye examination was 15.4 ± 0.7 years. The meanALwas 23.5 ± 0.9 mm, and the mean subfovealCTwas 369 ± 87 μm. Choroidal thickness (CT) was 331 ± 68 μm for the overall macula, 355 ± 78 μm for the 1‐mm zone and 304 ± 60 μm for the 3‐mm zone. AllCTmeasurements were thinner in myopic eyes (p < 0.0001) and in boys (p < 0.05). We found no association between totalPAand theCTby either mixed model analysis (p = 0.074) or linear regression by any intensity levels (p = 0.22, p = 0.15 and p = 0.43).Conclusion: Among adolescents aged 14–17 years, there was no association between objective PA exposures and the CT, AL or refractive error.